Daewoong Pharmaceutical Launches Botulinum Toxin NUCEIVA in Spain

Reporter Kim Jisun / approved : 2024-06-20 01:58:03
  • -
  • +
  • 인쇄

Daewoong Pharmaceutical

 

[Alpha Biz= Reporter Kim Jisun] Daewoong Pharmaceutical announced on the 19th that it will launch its botulinum toxin 'NUCEIVA' in Spain through its partner 'Evolus'.

With this, Daewoong Pharmaceutical's botulinum toxin has expanded its presence in Europe to a total of five countries: the UK, Germany, Austria, Italy, and now Spain. Europe is the second-largest botulinum toxin market after the United States.

Evolus, Daewoong Pharmaceutical's partner, will handle the distribution and marketing of NUCEIVA in Spain. They plan to support the rapid market penetration of NUCEIVA by offering various training programs for local healthcare professionals and providing online platforms.

 

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

주요기사

Hyundai Motor Securities Raises SK Hynix Target Price by 24.6% to KRW 405,0002025.09.17
Shinhan Investment & Securities Maintains ‘Buy’ Rating on Orion, Expects Sales Growth and Stock Recovery in Second Half2025.09.17
Samsung Securities Raises Target Price for L&F to KRW 100,000, Citing Stronger Fundamental Recovery2025.09.17
Hyundai Mobis Union Continues Strike Independently, Citing Broken Wage Agreement2025.09.17
Over KRW 1.5 Trillion in Pension Premiums Miscollected Over Past 5.5 Years2025.09.17
뉴스댓글 >